Terminate CA2+ Release by Local Inactivation of Ryanodine Receptors(RyR)in Heart

通过心脏中瑞尼定受体 (RyR) 的局部失活终止 CA2 释放

基本信息

项目摘要

SUMMARY OF WORK In cardiac myocytes, Ca2+ release from RyR in the sarcoplasmic reticulum (SR) is activated by the Ca2+-induced-Ca2+ release (CICR) mechanism. CICR, with its inherent positive feedback, is expected to operate in an "all-or-none" fashion. In order to generate Ca2+ transients of graded amplitude and robust stability, a regulatory mechanism must exist to counteract the regenerative CICR. Several mechanisms, including inactivation, adaptation, and stochastic closing of RyRs have been proposed, but no conclusive evidence has yet been documented. Our recent study has shown that FK506-binding protein (FKBP), an immunophilin and accessory protein of RyR, constitutes a prominent regulator of CICR via shortening the duration of the elementary release events (Ca2+ sparks) and accelerating the desensitization of RyR to Ca2+. However, the primary termination mechanism of CICR remained elusive. In the present study, we probed the termination process of Ca2+ release triggered by L-type Ca2+ channel using a novel fluorescent technique. By combination of a fast, linear Ca2+ indicator, Oregon Green BAPTA 5N, and a high concentration of Ca2+ chelator, EGTA, Ca2+ release was visualized as discrete "Ca2+ spikes" restricted toT tubule-SR junctions, each consisting of single or a few Ca2+ sparks. At 0 mV, Ca2+ spikes occurred and terminated within 40 ms following the onset of voltage clamp pulses. Increasing the open duration and promoting the reopenings of Ca2+ channels with the Ca2+ channel agonists, FPL64176, did not prolong or trigger secondary Ca2+ spikes, even though 2/3 of the SR Ca2+ remained available for release by caffeine. Latency analysis revealed that Ca2+ spikes coincided with the first openings, but not with the reopenings, of L-type Ca2+ channels. Furthermore, after an initial maximal release (e.g., at 0 mV), even a multi-fold increase in unitary Ca2+ current produced by a hyperpolarization step to -120 mV failed to trigger additional release, indicating an absolute refractoriness of RyRs. When the release was submaximal (e.g., at +30 mV), tail currents upon hyperpolarization did activate additional Ca2+ spikes; confocal images revealed that they originated from a different RyRs, i.e., those unfired during depolarization. These results indicate that Ca2+ release is terminated primarily by a highly localized, use-dependent inactivation of RyRs , but not by stochastic closing and adaptation of RyRs or depletion of SR Ca2+ in intact ventricular myocytes.
在心肌细胞中,Ca 2 + 肌浆网(SR)中RyR的释放被激活, Ca 2+诱导的Ca 2+释放(CICR)机制。CICR,其 固有的正反馈,预计将在一个 “全有或全无”的时尚。为了产生Ca 2+瞬变, 梯度振幅和强大的稳定性,监管机制必须 存在以抵消再生CICR。几种机制, 包括RyR的失活、适应和随机关闭 已经提出,但还没有确凿的证据, 记录在案。我们最近的研究表明,FK 506结合 蛋白(FKBP),一种亲免蛋白和RyR的辅助蛋白, 构成了一个突出的调节CICR通过缩短 基本释放事件(Ca 2+火花)的持续时间,以及 促进RyR对Ca ~(2+)的脱敏。但 CICR的主要终止机制仍不清楚。在 本研究探讨了Ca 2+释放的终止过程 用一种新的荧光探针, 法通过结合快速、线性的Ca 2+指示剂,俄勒冈州 绿色BAPTA 5 N和高浓度的Ca 2+螯合剂, EGTA,Ca 2+释放被可视化为离散的“Ca 2+尖峰”。 仅限于T管-SR连接,每个连接由单个或一个 少量Ca 2+火花。在0 mV时,出现并终止Ca 2+峰电位 在电压箝位脉冲开始后的40 ms内。 增加开放时间,促进Ca 2+再开放 Ca 2+通道激动剂FPL 64176的钙通道, 延长或触发继发性Ca 2+尖峰,即使2/3的 SR Ca 2+仍然可以通过咖啡因释放。延迟 分析显示Ca 2+尖峰与第一次开口一致, 但不与L-型Ca 2+通道的重新开放有关。此外,委员会认为, 在初始最大释放(例如,在0 mV),甚至是多倍 由超极化产生的单位Ca 2+电流增加 阶跃至-120 mV未能触发额外释放,表明 RyR的绝对不应期。当释放为次最大时 (e.g.,在+30 mV时),超极化后的尾电流确实激活 额外的Ca 2+尖峰;共聚焦图像显示, 源自不同的RyR,即,那些未被解雇的人 去极化这些结果表明,Ca 2+释放是 主要由高度本地化的、依赖于使用的 RyR的失活,但不是通过随机关闭和适应 RyRs或SR Ca ~(2+)耗竭。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heping (PEACE) Cheng其他文献

Heping (PEACE) Cheng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)
L 型钙通道 SNP rs1006737:表征 MUD(甲基苯丙胺使用障碍)的遗传风险
  • 批准号:
    10668210
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
  • 批准号:
    10603554
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
开发一种治疗阿片类药物使用障碍的新型钙通道疗法
  • 批准号:
    10684558
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
  • 批准号:
    10815882
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel Tools to Probe Trafficking and Function of Calcium Channel Signaling Complexes in Heart
探测心脏钙通道信号复合物的运输和功能的新工具
  • 批准号:
    10628914
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Mechanisms of L-type Calcium Channel Regulation in Heart Health and Disease
L 型钙通道在心脏健康和疾病中的调节机制
  • 批准号:
    10734121
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Structure-Function of Calcium Channel Complexes in Cardiac Physiology and Disease
钙通道复合物在心脏生理和疾病中的结构-功能
  • 批准号:
    10628911
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Research Initiation Award: Defining the role of DJ-1 in regulating L-type voltage-dependent calcium channel expression in neuronal plasticity
研究启动奖:定义 DJ-1 在调节神经元可塑性中 L 型电压依赖性钙通道表达中的作用
  • 批准号:
    2200474
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Design and Preclinical Development of First-in-Class Selective T-type Calcium Channel Blockers for Chronic Pain
用于治疗慢性疼痛的一流选择性 T 型钙通道阻滞剂的设计和临床前开发
  • 批准号:
    452107
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Preventing the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults
预防钙通道阻滞剂 – 下肢水肿 – 老年人袢利尿剂处方级联
  • 批准号:
    10399417
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了